Back
8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗8-K ↗CT.gov ↗8-K ↗CT.gov ↗CT.gov ↗CT.gov ↗CT.gov ↗8-K ↗8-K ↗8-K ↗8-K ↗
VRTX
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a biotechnology company developing medicines across multiple therapeutic areas including cystic fibrosis, sickle cell disease, beta thalassemia, and acute pain, with approved products already on the market in these areas. The pipeline includes mid- and late-stage clinical programs using various modalities to address kidney diseases (IgA nephropathy, APOL1-mediated disease, primary membranous nephropathy, and autosomal dominant polycystic kidney disease), neuropathic pain, type 1 diabetes, and myotonic dystrophy type 1. Five pivotal programs are currently advancing through clinical development, including povetacicept for IgA nephropathy, which has completed enrollment in Phase 3 testing.
$427.38-16.12%1Y
VRTX · daily close · illustrative · 0 catalysts marked
Pipeline
Unknownprimary membranous nephropathy
Unknownimmunoglobulin A nephropathy
UnknownGeneralized Myasthenia Gravis
UnknownIgA Nephropathy
UnknownIgA Nephropathy and Primary Membranous Nephropathy
UnknownMyasthenia Gravis, Generalized
Unknownimmunoglobulin A nephropathy (IgAN) in adults
Unknownautosomal dominant polycystic kidney disease
UnknownCystic Fibrosis
Unknownmyotonic dystrophy type 1
UnknownCystic Fibrosis
UnknownType 1 Diabetes
Catalyst Calendar
H1
INDpovetacicept
“Vertex expects to initiate a placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG in the first half of 2026.”
H1
Interimpovetacicept
“The interim analysis will be conducted once this cohort reaches 36 weeks of treatment, with the potential to file for Accelerated Approval in the U.S. in the first half of 2026, if results are supportive.”
H2
Enroll.povetacicept
“Vertex anticipates completing the Phase 2 portion of the study and initiating the Phase 3 portion in mid-2026.”
H2
Readoutinaxaplin
“Vertex is on track to complete dosing and share data from the AMPLIFIED study in the second half of 2026.”
H2
ReadoutVX-828
“Vertex is on track to complete dosing in this study in the first half of 2026 and share results in the second half.”
H2
ReadoutVX-670
“Vertex is on track to complete enrollment and dosing in the trial and share results in the second half of 2026.”
H2
ReadoutVX-522
“Vertex is targeting completion of dosing in the multiple ascending dose (MAD) portion of the Phase 1/2 study of VX-522 and disclosure of the data in the second half of 2026.”
H2
Enroll.inaxaplin
“The AMPLITUDE study is on track to complete full enrollment in the second half of 2026.”
H2
Enroll.VX-670
“Vertex is on track to complete enrollment and dosing in the trial in mid-2026.”
SEP 30
PDUFApovetacicept
“The Company used a priority review voucher and therefore expects the FDA review of the povetacicept BLA to be expedited to six months from the date of the FDA's acceptance of the BLA versus the typical ten-month review.”
DEC
Readoutinaxaplin
“A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease — primary completion 2026-12-30”
DEC 31
Enroll.suzetrigine
“Vertex is on track to complete enrollment in both Phase 3 studies of suzetrigine in diabetic peripheral neuropathy (DPN), a form of peripheral neuropathic pain (PNP), by the end of 2026.”
APR
Readoutsuzetrigine
“A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of the Efficacy and Safety of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy — primary completion 2027-04-06”
JUL
ReadoutVX-407
“A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants — primary completion 2027-07-22”
DEC
Readoutpovetacicept
“A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy — primary completion 2028-12-29”
MAR
Readoutpovetacicept
“A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a Long-term Extension of Povetacicept in Adults With Generalized Myasthenia Gravis — primary completion 2029-03-02”
Past (5)
AUG–AUG
Enroll.zimislecel
“Vertex is on track to complete enrollment and dosing in the Phase 3 portion of the Phase 1/2/3 global study of zimislecel in patients with T1D with severe hypoglycemic events and impaired awareness of hypoglycemia in the near term.”
NOV
NDApovetacicept
“Vertex is on track to submit the first module of the IgAN BLA to the FDA before the end of 2025”
NOV 08
Conf.povetacicept
“Vertex will have an oral presentation of updated Phase 1/2 data on povetacicept in IgAN and pMN at the American Society of Nephrology (ASN) Kidney Week. Vertex will host an in-person investor event at the ASN conference on Saturday, November 8, 2025, at 7:00 p.m. CT / 8:00 p.m. ET.”
MAR 31
NDApovetacicept
“Vertex Pharmaceuticals Incorporated (the "Company") has completed the submission to the U.S. Food and Drug Administration (the "FDA") of its rolling Biologics Licensing Application ("BLA") for potential accelerated approval of povetacicept for the treatment of immunoglobulin A nephropathy ("IgAN") in adults.”